Credit and interest ratesmixed · 4 filings
“We expect net interest expense for the full year 2026 to increase to approximately $40 million, primarily due to lower interest income.”10-Q · May 6, 2026 ↗
Insulet Corporation
PODD
Market read
Insulet Corporation's current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 28 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 9 directly disclosed connections are confirming.
Company-3.9% todayVolume comparison unavailable
Market group0 of 28 activeEquity Risk · unavailable
Disclosed network0 of 8 confirmingNo filing-linked name is confirming now
What would change this read
Watch this read- Monitor the reported 45.2% revenue increase excluding 14.2% FX and its attribution to higher volumes from a growing customer base and higher Omnipod 5 ASP vs Omnipod DASH.
- Monitor higher interest expense tied to issued 6.5% senior notes and renewed swaps and the company’s ~ $40M net interest expense expectation for 2026.
Invalidation: The isolated read changes if PODD's group or a disclosed connection begins moving with it.
Research brief
The story so far
No new filing conclusion is available. 0 of 28 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 9 directly disclosed connections are confirming.
Evidence that supports
No thresholded supportive filing evidence is available yet.
Evidence that challenges
No thresholded adverse filing evidence is available yet.
What would clarify the read
- Monitor the reported 45.2% revenue increase excluding 14.2% FX and its attribution to higher volumes from a growing customer base and higher Omnipod 5 ASP vs Omnipod DASH.
- Monitor higher interest expense tied to issued 6.5% senior notes and renewed swaps and the company’s ~ $40M net interest expense expectation for 2026.
Company research
Understand the business, not just the ticker
Business model and earnings drivers
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
Key research questions
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
Annual periods9
Price observations601
Usable filing statements108
Verified relationships7
Evidence supporting the case
- Latest annual revenue changed +30.7% year over year.
- Operating margin changed +2.6 percentage points in the latest annual period.
- Operating cash flow covered net income at 2.30x in the latest annual period.
- Demand and volume has repeated favorable evidence across 4 filings.
- Foreign exchange has repeated favorable evidence across 4 filings.
Evidence challenging the case
- Net margin changed -11.1 percentage points in the latest annual period.
- Product pipeline and R&D has repeated adverse evidence across 4 filings.
Questions before a position
- P/E is 36% above the available filing-peer median; determine whether growth and quality justify the difference.
- EV/sales is 69% above the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context
Price as of Sep 10, 2026
134.696m-43.6%12m-61.8%24m-37.7%
Annual trajectory
Reported annual revenue and per-share history. This is accounting history, not a forecast.
PeriodRevenueYoYDiluted EPSShare change
2021-12-31$1.1B+21.5%$0.24+4.0%
2022-12-31$1.3B+18.8%$0.07+1.9%
2023-12-31$1.7B+30.0%$2.94+5.3%
2024-12-31$2.1B+22.1%$5.78+0.4%
2025-12-31$2.7B+30.7%$3.48-2.7%
What management says matters
Persistent and emerging business drivers
Demand and volumepositive · 4 filings
“Excluding the 14.2% favorable impact of currency exchange, the remaining 45.2% increase in revenue was primarily due to higher volumes from our growing customer base, and to a lesser extent, a higher average selling price for Omnipod 5, compared with Omnipod…”10-Q · May 6, 2026 ↗
Foreign exchangepositive · 4 filings
“Excluding the 14.2% favorable impact of currency exchange, the remaining 45.2% increase in revenue was primarily due to higher volumes from our growing customer base, and to a lesser extent, a higher average selling price for Omnipod 5, compared with Omnipod…”10-Q · May 6, 2026 ↗
Legal and regulatory exposurepositive · 4 filings
“The injunction prohibits Defendants and others subject to the order from using, possessing, selling, distributing, or seeking regulatory approval for any products that were designed, developed, or manufactured, in whole or in part, using or relying on Insulet…”10-Q · May 6, 2026 ↗
Valuation discipline
Descriptive valuation snapshot
Price/sales 3.6× · EV/sales 3.6×. Comparisons use only industry-matched filing peers.
Scenario scaffold
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
How the market is pricing the story
132.47-3.9% today
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 15:10 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for PODD. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for PODD. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind PODD
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
AMGN21.0% of PODDcustomerMay 6, 2026 ▾
“21 Table of Contents Drug Delivery Substantially all of our Drug Delivery revenue consists of sales of pods to Amgen for use in the Neulasta ® Onpro ® kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.”
ABTAbbott LaboratoriessupplierNov 6, 2025 ▾
“Further, we integrated Omnipod 5 with Dexcom’s G7 CGM sensor in Germany, Sweden, Denmark, Finland and Italy, and with Abbott’s FreeStyle Libre 2 Plus sensor in Australia.”
Depended on by
TNDMTandem Diabetes Care, Inc.competitorMay 7, 2026 ▾
“We compete in markets worldwide with companies that manufacture insulin delivery devices, primarily Beta Bionics, Insulet, Medtronic, mylife (formerly Ypsomed) and Sequel.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 7 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
PODD is currently a Participant in the organic co-movement group Equity Risk. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for PODD; it is not active in the latest market snapshot.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.